July 2025
Karyopharm Therapeutics - United States - 20% workforce
Issued its second round of layoffs this year as strategic options failed to materialize.Pacira - San Diego, California - 71 employees (8%)
Shut down its Exparel production facility, eliminating 71 roles at its science campus.Jasper Therapeutics - United States - 50% workforce
Cut half its staff after a faulty dr-g batch disrupted clinical trials and triggered reorganization.Century Therapeutics - United States - 51% workforce
Eliminated over half of its team to focus on highest-potential programs and terminated two executives.CSL - Multiple biotech hubs - Undisclosed number
Consolidated R&D around six core sites, laying off unspecified employees during restructuring.4D Molecular Therapeutics - United States - 25% workforce
Laid off a quarter of staff to save $15 million annually and shift focus to late-stage development.
June 2025
Apple Tree Partners - United States - Potentially hundreds
Faced investor funding disruption leading to confirmed and anticipated widespread layoffs.Bristol Myers Squibb - Lawrenceville, New Jersey - 68 employees
Continued cost-cutting at its New Jersey site with phased layoffs through early 2026.Sage Therapeutics - United States - 338 employees
Laid off entire workforce ahead of planned acquisition by Supernus Pharmaceuticals.BlueRock Therapeutics - Cambridge, Massachusetts - 50 employees
Closed Cambridge research labs while maintaining operations in New York and Toronto.Leap Therapeutics - United States - 75% workforce
Increased layoffs to 75% while shutting down its sole remaining clinical trial.Prothena - Ireland - 63% workforce
Cut most of its team after failure of a phase 3 trial for amyloidosis treatment.BioNTech - Gaithersburg, Maryland - 63 employees
Ended manufacturing at the site after ending a cancer trial program.Scorpion Therapeutics - United States - Undisclosed number
Reduced staff post-spinout and restructuring following program sale to Eli Lilly.Gilead Sciences - California - 36 employees
Scrapped plans to expand a biologics facility and laid off supporting staff.ADC Therapeutics - United Kingdom - 30% workforce
Closed U.K. R&D site after discontinuing its lead clinical candidate.Vertex Pharmaceuticals - Providence, Rhode Island - 125 employees
Consolidated operations and shut its Rhode Island gene therapy site.Genentech - South San Francisco, California - 143 employees
Continued phased layoffs at a major Roche-owned facility.Recursion Pharmaceuticals - United States - 20% workforce
Reduced headcount as part of an oncology-focused restructuring.Rapt Therapeutics - Bay Area, California - Undisclosed number
Made a second round of cuts following a halted lead immunology asset.Plexium - United States - Undisclosed number
Realigned staff to support its cancer-focused preclinical pipeline.
May 2025
Keros Therapeutics - Massachusetts - 45% workforce
Ended a phase 2 program and reduced headcount nearly in half.Stealth BioTherapeutics - United States - 30% workforce
Reduced staff after FDA rejection and delay in approval process.iTeos Therapeutics - United States - Undisclosed number
Wound down operations after loss of key partnership with GSK.Boundless Bio - United States - ~33% workforce
Laid off around 20 people after disappointing trial data.Eikon Therapeutics - California - 15% workforce
Cited government funding constraints in decision to eliminate jobs.Schrödinger - United States - 60 employees (7%)
Cut staff to conserve cash and improve operational efficiency.Prime Medicine - United States - 25% workforce
Shelved its sole clinical-stage program and CEO resigned.RA Ventures - United States - Undisclosed number
Conducted layoffs at its biotech incubator unit.Allogene - United States - 28% workforce
Focused on two clinical programs while significantly reducing staff.Kyverna Therapeutics - United States - 16% workforce
Restructured to prioritize late-stage CAR-T program.Leap Therapeutics - Massachusetts - 50% workforce
Halved staff to narrow focus on its lead cancer dr-g.Atara Biotherapeutics - United States - 30% of remaining staff
Follow-up to earlier cuts, leaving only essential roles.10x Genomics - United States - 8% workforce
Adjusted headcount due to unpredictable academic funding.NGM Bio - United States - 75% workforce
Paused all R&D and eliminated most research positions.Lexeo Therapeutics - United States - 15% workforce
Trimmed staff to fund core cardiac gene therapy programs.Teva Pharmaceuticals - United States - 8% workforce
Announced multiyear cost savings initiative with staff cuts.IGM Biosciences - United States - 80% workforce
Shut down nearly all operations after partner Sanofi pulled out.Insitro - South San Francisco, California - 22% workforce
Reduced team size to extend cash runway to 2027.Vor Bio - United States - 95% workforce
Closed most operations and retained minimal staff for sale options.Korro Bio - United States - 20% workforce
Shifted funding to its lead genetic disease program.Shape Therapeutics - Seattle, Washington - Undisclosed number
Streamlined workforce during six-month pipeline refocus.RallyBio - United States - 40% workforce
Made deep cuts after dropping its lead dr-g in April.Mersana Therapeutics - United States - 55% workforce
Refocused business around a br---t cancer program.Bristol Myers Squibb - Lawrenceville, New Jersey - 516 employees
Conducted large-scale layoffs as part of broader restructuring.Biomea Fusion - San Carlos, California - 35% workforce
Shifted focus away from leukemia and consolidated teams.Unity Biotechnology - Bay Area, California - 100% workforce
Fully eliminated staff while exploring strategic alternatives.Mammoth Biosciences - California - 24 employees
Conducted layoffs as part of a strategic realignment.Pliant Therapeutics - United States - 45% workforce
Extended runway by reducing staff after dr-g safety concerns.Arvinas - United States - 33% workforce
Cut staff after halting two phase 3 trials with Pfizer.
April 2025
Lisata Therapeutics - United States - 4 employees
Eliminated four R&D roles as several clinical trials concluded.Entrada - United States - 20% workforce
Cut staff to prioritize pipeline following FDA lift of trial hold.Ono Pharma - Cambridge, Massachusetts - 83 employees
Reduced headcount at its U.S. site, effective June 30.Octagon Therapeutics - United States - Undisclosed number
Shut down after deprioritizing its lead program and facing scientific uncertainty.Spruce Biosciences - United States - 55% workforce
Slashed more than half its team after pivoting to a new licensed asset.Caribou Biosciences - United States - 32% workforce
Cut staff and dropped a CAR-T asset to focus on two lead candidates.Tempest Therapeutics - United States - 80% workforce
Reduced team to just five employees to stretch cash reserves.Mural Oncology - United States - 104 employees (90%)
Laid off most of the workforce after IL-2 dr-g failure.Third Harmonic Bio - United States - Undisclosed number
Abandoned lead dr-g and prepared to liquidate the business.Pfizer - San Diego, California - 56 employees
Laid off staff after selling its five-building Torrey Pines campus.Opthea - United States - 65% workforce
Announced deep staff cuts and operational scaling after dr-g failure.Organon - New Jersey - 93 employees
Cut staff as part of an ongoing revamp since 2023.Vincerx Pharma - United States - Undisclosed number
Began winding down operations after two failed merger attempts.Tango Therapeutics - United States - 30 employees
Reduced spending on preclinical work and cut staff accordingly.Lyell Immunopharma - Los Angeles, California - 73 employees
Closed ImmPact Bio's manufacturing facility after acquisition.Roche - Santa Clara, California - 108 employees
Cut positions in its diagnostics division focused on R&D and software.Gilead - Foster City, California - 149 employees
Initiated layoffs at headquarters, to take effect in May.Relay Therapeutics - Massachusetts - 70 employees
Third round of layoffs, part of a broader 75% R&D budget reduction.Oncodesign Precision Medicine - France - 5 employees
Made cuts after losing a partnership with Servier.Sail Biomedicines - United States - 12 employees
Reduced headcount following internal structural review.
March 2025
Carisma Therapeutics - United States - 40 employees (approx)
Reduced headcount from 46 to 6 as it seeks strategic alternatives.Inspirna - United States - Dozens of employees
Shut down operations, eliminating all staff.LifeMine Therapeutics - United States - Undisclosed number
Slimmed down staff to focus on its lead clinical candidate.BioAtla - United States - Over 30% workforce
Restructured to prioritize core programs and reduce costs.Nkarta - South San Francisco, California - 53 employees (34%)
Laid off a third of workforce including half of executive leadership.Arbutus Biopharma - United States - Undisclosed number
Retained only a core team to support hepatitis B trials.Lyndra Therapeutics - United States - 60 employees
Wound down operations after failed financing attempts.ElevateBio - United States - 17% workforce
Conducted layoffs to position for long-term success.Vaxart - South San Francisco, California - 10% workforce
Cut jobs after government halted COVID-19 pill trial.Elevation Oncology - United States - 70% workforce
Made deep cuts after scrapping its sole clinical asset.bit.bio - United Kingdom - 25% workforce
Pivoted toward biomedical tools, resulting in layoffs.Cargo Therapeutics - United States - 90% workforce
Made second major cut after abandoning its lead asset.Empress Therapeutics - Massachusetts - 23 employees (50%)
Cut half of team due to delays in dr-g development progress.TC BioPharm - Scotland - 20 employees
Outsourced functions and reduced workforce accordingly.HC Bioscience - United States - Undisclosed number
Shut down after preclinical results failed to deliver.Pyxis Oncology - Boston, Massachusetts - 20% workforce
Reduced headcount after cutting pipeline to one cancer asset.Novartis - East Hanover, New Jersey - 427 employees
Reduced workforce as part of a restructuring in cardiovascular sales.Merck & Co. - Riverside, Pennsylvania - 163 employees
Phased out jobs at Cherokee plant during multi-year closure plan.Apriori Bio - United States - 15 employees
Reduced workforce during shift from platform to pipeline focus.Sutro Biopharma - United States - Nearly 50% workforce
Cut staff and replaced CEO after deprioritizing lead asset.GRO Biosciences - United States - Undisclosed number
Restructured and eliminated roles in research.Kiromic BioPharma - United States - 31 employees
Furloughed nearly all staff amid a cash crisis.Atea Pharmaceuticals - United States - 25% workforce
Cut jobs to save $15 million after exiting COVID dr-g development.ALX Oncology - United States - 30% workforce
Focused on trials for CD47 blocker and reduced operating costs.Bristol Myers Squibb - Lawrenceville, NJ and Redwood City, CA - 280 employees
Rolled out new waves of layoffs in two states.Atara Biotherapeutics - United States - 50% workforce
Halved headcount after FDA halted trials of two key assets.
February 2025
CRISPR Therapeutics - United States - Undisclosed number
Quietly laid off employees across research and manufacturing.Eisai - United States - 121 employees
Restructured U.S. operations and eliminated commercial roles.Ryvu Therapeutics - Poland - 30% workforce
Focused remaining resources on phase 3 blood cancer dr-g.Lava Therapeutics - United States - 30% workforce
Cut jobs after terminating lead blood cancer program.Repare Therapeutics - United States - 75% workforce
Conducted major layoffs following earlier announcements.Spotlight Therapeutics - San Francisco, California - All employees
Shut down company operations entirely.Kojin Therapeutics - Boston, Massachusetts - Undisclosed number
Began winding down and prepared to close over coming months.Moderna - United States - 50 employees (10% of IT team)
Cut digital department roles after CIO's departure.Encoded Therapeutics - United States - 29% workforce
Focused resources on Dravet syndrome and eliminated early R&D roles.Inventiva - France - 50% workforce
Reduced staff to concentrate on MASH dr-g development.Third Harmonic Bio - United States - 50% workforce
Scaled down in preparation for next clinical stage.Q32 Bio - United States - Undisclosed number
Cut workforce and paused programs to conserve cash.X4 Pharmaceuticals - United States and Austria - 43 employees (30%)
Closed Vienna site and paused all pre-clinical efforts.Viracta Therapeutics - San Diego, California - All employees
Closed the company and laid off full staff.Frontier Medicines - United States - Undisclosed number
Streamlined operations for efficiency and impact.Kyowa Kirin - Princeton, New Jersey - 52 employees
Conducted layoffs at its North American headquarters.Bristol Myers Squibb - New Jersey - 67 employees
Continued layoffs under ongoing cost-cutting plan.Turnstone Biologics - San Diego, California - Undisclosed number
Reduced workforce while seeking strategic alternatives.Omega Therapeutics - United States - Up to 17 employees
Faced possible bankruptcy and workforce reduction.
January 2025
Cargo Therapeutics - United States - 50% workforce
Cut jobs after discontinuing lead candidate with weak results.Ironwood Pharmaceuticals - United States - 50% workforce
Halved staff to focus on investigational bowel syndrome treatment.I-Mab - United States - 27% workforce
Restructured pipeline and reduced staff accordingly.Zentalis Pharmaceuticals - United States - 40% workforce
Reduced headcount to extend cash through 2026.Allakos - United States - 75% workforce
Made deep cuts after lead dr-g failed in phase 1.Biogen - United States - Undisclosed number
Reallocated resources by reducing research team.Notch Therapeutics - Canada - Undisclosed number
Made layoffs due to fundraising and partnership struggles.Apellis Pharmaceuticals - Global (non-US) - 40 employees
Prioritized U.S. commercialization and cut international roles.Barinthus Bio - US and UK - 65% workforce
Halted hepatitis B program and reduced headcount substantially.Passage Bio - Philadelphia, Pennsylvania - 55% workforce
Shifted from in-house to outsourced testing model.Y-mAbs Therapeutics - Denmark and US - Up to 13% workforce
Relocated and consolidated roles as part of a reorganization.Repare Therapeutics - United States - Undisclosed number
Followed up previous layoff with additional undisclosed cuts.Intellia Therapeutics - United States - 27% workforce
Reduced headcount and paused pipeline to aim for 2027 launch.Shoreline Biosciences - United States - Undisclosed number
Cut employees from a discontinued collaboration with Gilead.IGM Biosciences - United States - 73% workforce
Refocused on autoimmune diseases and closed most operations.Velia Therapeutics - United States - Undisclosed number
Wound down company operations entirely.Scribe Therapeutics - United States - 20% workforce
Cut roles while advancing clinical development plans.Galapagos - United States and Europe - 40% workforce (approx. 300 employees)
Restructured by splitting company into two divisions.Cassava Sciences - United States - 33% workforce
Reduced staff after Alzheimer’s trial failure.CytomX Therapeutics - California - 40% workforce
Cut staff and reassessed strategic partnerships.